Intravitreal ganciclovir implant for the treatment of cytomegalovirus retinitis

Richard H. Fish, J. F. Gordon, David M. Brown, V. W. Teeters

Research output: Contribution to journalReview articlepeer-review

1 Scopus citations


Cytomegalovirus (CMV) retinitis is the most common infection of the eye in patients with the acquired immune deficiency syndrome. In addition to the two standard modes of treatment-intravenous ganciclovir and intravenous foscarnet - a new method of drug delivery to the eye has been developed and extensively tested. The intravitreal ganciclovir implant (Vitrasert) consists of a pellet of ganciclovir coated with inert polymers designed to control the release of the drug into the eye. The ganciclovir implant has been shown to significantly extend the time to progression of CMV retinitis and is associated with a low rate of complications. This article outlines the design, release characteristics, and complications associated with the ganciclovir implant and reviews the results of recently completed clinical trials. Recommendations for surgical implantation and future directions for research are also discussed.

Original languageEnglish (US)
Pages (from-to)35-44
Number of pages10
JournalOphthalmology Clinics of North America
Issue number1
StatePublished - Jan 1 1997

ASJC Scopus subject areas

  • Ophthalmology


Dive into the research topics of 'Intravitreal ganciclovir implant for the treatment of cytomegalovirus retinitis'. Together they form a unique fingerprint.

Cite this